Lifecore Net Debt from 2010 to 2024
| LFCR Stock | 7.46 0.15 2.05% |
Net Debt | First Reported 1996-02-29 | Previous Quarter 121.9 M | Current Value 131.3 M | Quarterly Volatility 69.3 M |
Check Lifecore Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lifecore Biomedical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 6.4 M, Interest Expense of 19 M or Total Revenue of 121.8 M, as well as many indicators such as Price To Sales Ratio of 0.21, Dividend Yield of 0.0 or PTB Ratio of 0.7. Lifecore financial statements analysis is a perfect complement when working with Lifecore Biomedical Valuation or Volatility modules.
Lifecore | Net Debt |
Latest Lifecore Biomedical's Net Debt Growth Pattern
Below is the plot of the Net Debt of Lifecore Biomedical over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Lifecore Biomedical's Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lifecore Biomedical's overall financial position and show how it may be relating to other accounts over time.
| Net Debt | 10 Years Trend |
|
Net Debt |
| Timeline |
Lifecore Net Debt Regression Statistics
| Arithmetic Mean | 94,538,193 | |
| Coefficient Of Variation | 78.38 | |
| Mean Deviation | 64,455,540 | |
| Median | 70,042,000 | |
| Standard Deviation | 74,094,605 | |
| Sample Variance | 5490T | |
| Range | 234.5M | |
| R-Value | 0.79 | |
| Mean Square Error | 2256.8T | |
| R-Squared | 0.62 | |
| Significance | 0.0005 | |
| Slope | 13,027,712 | |
| Total Sum of Squares | 76860.1T |
Lifecore Net Debt History
Other Fundumenentals of Lifecore Biomedical
Lifecore Biomedical Net Debt component correlations
Click cells to compare fundamentals
About Lifecore Biomedical Financial Statements
Lifecore Biomedical shareholders use historical fundamental indicators, such as Net Debt, to determine how well the company is positioned to perform in the future. Although Lifecore Biomedical investors may analyze each financial statement separately, they are all interrelated. The changes in Lifecore Biomedical's assets and liabilities, for example, are also reflected in the revenues and expenses on on Lifecore Biomedical's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Debt | 121.9 M | 128 M | |
| Net Debt To EBITDA | 3.42 | 2.04 |
Pair Trading with Lifecore Biomedical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lifecore Biomedical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lifecore Biomedical will appreciate offsetting losses from the drop in the long position's value.Moving against Lifecore Stock
| 0.81 | TCHH | Trustcash Holdings | PairCorr |
| 0.8 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.8 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.79 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.78 | AGL | agilon health Buyout Trend | PairCorr |
The ability to find closely correlated positions to Lifecore Biomedical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lifecore Biomedical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lifecore Biomedical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lifecore Biomedical to buy it.
The correlation of Lifecore Biomedical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lifecore Biomedical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lifecore Biomedical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lifecore Biomedical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.